<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02285270</url>
  </required_header>
  <id_info>
    <org_study_id>819607</org_study_id>
    <nct_id>NCT02285270</nct_id>
  </id_info>
  <brief_title>Circadian Brown Adipose Tissue Metabolism</brief_title>
  <official_title>A Pilot Study to Investigate Circadian Variations in Brown Adipose Tissue Metabolism in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brown adipose tissue is poorly understood fat that can metabolize glucose in order to
      generate heat. Since activated brown fat has a high metabolic rate, it is of great interest
      as a potential target to combat obesity. However, the signaling and control of brown fat
      metabolism is poorly understood. Because brown fat uses glucose as its energy source, brown
      fat metabolism can be imaged with PET/CT using the positron emitting glucose analog F-18 FDG.
      We have recently shown in mice a striking circadian variation in brown fat metabolism as
      evidenced by changes in FDG uptake. In this study we endeavor to generate pilot data on a
      potential circadian variation in brown fat activation in healthy humans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Brown adipose tissue is a form of fat that is able to metabolize glucose in order to generate
      heat. When active, it can convert a great deal of glucose into thermal energy. Activation of
      brown fat could potentially help to combat obesity by increasing the basal metabolic rate.
      However, activation and signaling of brown fat is poorly understood. In a mouse model, we
      have recently shown that there is significant circadian variation in brown fat activation and
      have also discovered the gene that is responsible for the circadian changes (Gerhart-Hines et
      al, Nature 2013). Specifically, we have shown that in wild type mice, brown fat activation is
      high at night and low during the day. Whether human brown fat activation has a circadian
      component is currently unknown. Showing that brown fat activation in humans is subject to
      similar circadian rhythms as in mice would be an important step in understanding the
      signaling of activation and may help to elucidate potential strategies to control activation.
      Positron emission tomography/computed tomography (PET/CT) is a hybrid imaging modality that
      allows imaging positron emitting isotopes such as fluorine-18 (F-18) along with anatomic
      imaging using x-rays. The physiologic information from the PET component is co-registered
      with the anatomic information from the CT component, permitting accurate localization and
      quantification of physiologic processes. The most common clinically used positron emitting
      radiopharmaceutical is F-18 fluorodeoxyglucose (FDG). It is a glucose analog which is taken
      up by glucose transporters and phosphorylated to FDG-6P by hexokinase. However, isomerase,
      the next enzyme in the glycolytic pathway, is inactive on FDG-6P and so it is largely trapped
      in the cell. Therefore, FDG PET/CT gives a map of relative amount of glucose uptake and
      phosphorylation over the interval from injection to scan. Activated brown fat has robust FDG
      uptake with very intense signal seen. Therefore, FDG PET/CT can be used both to determine
      whether a person has activated brown fat at the time of the scan as well as to quantify the
      overall level of metabolism in the fat. Our primary objective is to gather pilot data on the
      potential presence of circadian variations in brown fat uptake in young, healthy, lean male
      volunteers. We plan to do this by performing two FDG PET/CT scans 12 hours apart while the
      patient remains in a temperature and diet controlled environment leading up to both scans.
      Our primary hypothesis is that brown fat activity will be higher during the day than at night
      (as human and mouse circadian rhythms are reversed). We will also pair measurement of
      cortisol with the FDG injections as cortisol levels provide valuable independent information
      on the circadian rhythm.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Maximum Standardized Update Value (SUVmax) in Brown Adipose Tissue FDG Uptake in the Neck or Upper Chest on Evening and Imaging Compared to Morning Imaging</measure>
    <time_frame>~12-hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation Between Cortisol Level and Brown Adipose Tissue FDG Uptake</measure>
    <time_frame>~12-hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Brown Adipose Tissue FDG Uptake as Measured by Total Volume of Segmented Fat Times the Mean Standardized Uptake Value (SUVmean)</measure>
    <time_frame>~12-hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single group assignment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Diagnostic test/procedure - FDG PET/CT</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FDG PET/CT</intervention_name>
    <description>PET/CT is a hybrid imaging modality that allows imaging positron emitting isotopes such as F-18 along with anatomic imaging using x-rays. The physiologic information from the PET component is co-registered with the anatomic information from the CT component, permitting accurate localization and quantification of physiologic processes. The most common clinically used positron emitting radiopharmaceutical is F-18 fluorodeoxyglucose (FDG). It is a glucose analog which is taken up by glucose transporters and phosphorylated to FDG-6P by hexokinase. FDG PET/CT gives a map of relative amount of glucose uptake and phosphorylation over the interval from injection to scan.</description>
    <arm_group_label>Single group assignment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age and less than 45 years of age

          -  Able and willing to provide informed consent

          -  Male gender

          -  Capable of complying with study procedures and able to lie still in the PET/CT scanner
             for up to 40 minutes continuously

          -  Normal fasting glucose (less than 100 mg/dl)

          -  No evidence of significant concurrent illness

          -  Follow typical sleep/wake cycle of generally asleep at night and awake during the day

        Exclusion Criteria:

          -  Prior surgery or radiation to the head, neck, or upper chest (except surgeries such as
             tonsillectomy/adenoidectomy/tympanostomy that would not be expected, in the judgement
             of the investigator, to have disrupted the adipose tissue in the neck or the upper
             chest)

          -  Active addiction or illicit drug abuse

          -  BMI greater than 25

          -  Employment in the night shift/3rd shift

          -  Unable to remain in the Clinical and Translational Research Center (CTRC) for entire
             24 hour period.

          -  Unable or unwilling to maintain peripheral intravenous access for up to 24 hours

          -  Abnormal liver or kidney function (serum creatinine or transaminase levels greater
             than 1.5 ULN)

          -  Subject has any other condition or personal circumstance that, in the judgement of the
             investigator, might interfere with the collection of complete, high quality data
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Pryma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nature.com/nature/journal/v503/n7476/full/nature12642.html</url>
    <description>The nuclear receptor Rev-erbÎ± controls circadian thermogenic plasticity.</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2014</study_first_submitted>
  <study_first_submitted_qc>November 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2014</study_first_posted>
  <results_first_submitted>May 11, 2016</results_first_submitted>
  <results_first_submitted_qc>May 11, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2016</results_first_posted>
  <last_update_submitted>October 25, 2016</last_update_submitted>
  <last_update_submitted_qc>October 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Daniel Pryma</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <keyword>Circadian rhythm</keyword>
  <keyword>Adipose tissue, brown</keyword>
  <keyword>Metabolism</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Group Assignment</title>
          <description>Diagnostic test/procedure - FDG PET/CT
FDG PET/CT: PET/CT is a hybrid imaging modality that allows imaging positron emitting isotopes such as F-18 along with anatomic imaging using x-rays. The physiologic information from the PET component is co-registered with the anatomic information from the CT component, permitting accurate localization and quantification of physiologic processes. The most common clinically used positron emitting radiopharmaceutical is F-18 fluorodeoxyglucose (FDG). It is a glucose analog which is taken up by glucose transporters and phosphorylated to FDG-6P by hexokinase. FDG PET/CT gives a map of relative amount of glucose uptake and phosphorylation over the interval from injection to scan.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Determined to be ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Group Assignment</title>
          <description>Diagnostic test/procedure - FDG PET/CT
FDG PET/CT: PET/CT is a hybrid imaging modality that allows imaging positron emitting isotopes such as F-18 along with anatomic imaging using x-rays. The physiologic information from the PET component is co-registered with the anatomic information from the CT component, permitting accurate localization and quantification of physiologic processes. The most common clinically used positron emitting radiopharmaceutical is F-18 fluorodeoxyglucose (FDG). It is a glucose analog which is taken up by glucose transporters and phosphorylated to FDG-6P by hexokinase. FDG PET/CT gives a map of relative amount of glucose uptake and phosphorylation over the interval from injection to scan.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Maximum Standardized Update Value (SUVmax) in Brown Adipose Tissue FDG Uptake in the Neck or Upper Chest on Evening and Imaging Compared to Morning Imaging</title>
        <time_frame>~12-hours</time_frame>
        <population>No patients were analyzed since no patient showed uptake of FDG in brown adipose tissue.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Group Assignment</title>
            <description>Diagnostic test/procedure - FDG PET/CT
FDG PET/CT: PET/CT is a hybrid imaging modality that allows imaging positron emitting isotopes such as F-18 along with anatomic imaging using x-rays. The physiologic information from the PET component is co-registered with the anatomic information from the CT component, permitting accurate localization and quantification of physiologic processes. The most common clinically used positron emitting radiopharmaceutical is F-18 fluorodeoxyglucose (FDG). It is a glucose analog which is taken up by glucose transporters and phosphorylated to FDG-6P by hexokinase. FDG PET/CT gives a map of relative amount of glucose uptake and phosphorylation over the interval from injection to scan.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Maximum Standardized Update Value (SUVmax) in Brown Adipose Tissue FDG Uptake in the Neck or Upper Chest on Evening and Imaging Compared to Morning Imaging</title>
          <population>No patients were analyzed since no patient showed uptake of FDG in brown adipose tissue.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Between Cortisol Level and Brown Adipose Tissue FDG Uptake</title>
        <time_frame>~12-hours</time_frame>
        <population>No patients were analyzed since no patient showed uptake of FDG in brown adipose tissue.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Group Assignment</title>
            <description>Diagnostic test/procedure - FDG PET/CT
FDG PET/CT: PET/CT is a hybrid imaging modality that allows imaging positron emitting isotopes such as F-18 along with anatomic imaging using x-rays. The physiologic information from the PET component is co-registered with the anatomic information from the CT component, permitting accurate localization and quantification of physiologic processes. The most common clinically used positron emitting radiopharmaceutical is F-18 fluorodeoxyglucose (FDG). It is a glucose analog which is taken up by glucose transporters and phosphorylated to FDG-6P by hexokinase. FDG PET/CT gives a map of relative amount of glucose uptake and phosphorylation over the interval from injection to scan.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Cortisol Level and Brown Adipose Tissue FDG Uptake</title>
          <population>No patients were analyzed since no patient showed uptake of FDG in brown adipose tissue.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Brown Adipose Tissue FDG Uptake as Measured by Total Volume of Segmented Fat Times the Mean Standardized Uptake Value (SUVmean)</title>
        <time_frame>~12-hours</time_frame>
        <population>No patients were analyzed since no patient showed uptake of FDG in brown adipose tissue.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Group Assignment</title>
            <description>Diagnostic test/procedure - FDG PET/CT
FDG PET/CT: PET/CT is a hybrid imaging modality that allows imaging positron emitting isotopes such as F-18 along with anatomic imaging using x-rays. The physiologic information from the PET component is co-registered with the anatomic information from the CT component, permitting accurate localization and quantification of physiologic processes. The most common clinically used positron emitting radiopharmaceutical is F-18 fluorodeoxyglucose (FDG). It is a glucose analog which is taken up by glucose transporters and phosphorylated to FDG-6P by hexokinase. FDG PET/CT gives a map of relative amount of glucose uptake and phosphorylation over the interval from injection to scan.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Brown Adipose Tissue FDG Uptake as Measured by Total Volume of Segmented Fat Times the Mean Standardized Uptake Value (SUVmean)</title>
          <population>No patients were analyzed since no patient showed uptake of FDG in brown adipose tissue.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 4 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Single Group Assignment</title>
          <description>Diagnostic test/procedure - FDG PET/CT
FDG PET/CT: PET/CT is a hybrid imaging modality that allows imaging positron emitting isotopes such as F-18 along with anatomic imaging using x-rays. The physiologic information from the PET component is co-registered with the anatomic information from the CT component, permitting accurate localization and quantification of physiologic processes. The most common clinically used positron emitting radiopharmaceutical is F-18 fluorodeoxyglucose (FDG). It is a glucose analog which is taken up by glucose transporters and phosphorylated to FDG-6P by hexokinase. FDG PET/CT gives a map of relative amount of glucose uptake and phosphorylation over the interval from injection to scan.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daniel Pryma</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-349-5272</phone>
      <email>daniel.pryma@uphs.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

